Current disease status-First occurrence of the lymphoma Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the lymphoma Posts on Medivizor

Is R-CVP safer and more effective than R-CHOP for patients with painless NHL?

Posted by on Feb 5, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of two different chemotherapy regimens for patients with indolent (painless) non-Hodgkin’s lymphoma (NHL). This study found that the R-CVP regimen was similarly effective and had fewer side effects compared to R-CHOP for these patients. Some background Chemoimmunotherapy is the...

Read More

Are prognostic scores still useful for predicting outcomes for patients with advanced Hodgkin’s lymphoma?

Posted by on Jan 8, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined if international prognostic scores (IPS) could help predict treatment outcomes for patients with advanced Hodgkin's lymphoma (HL). The authors found that the IPS system is losing its predictability as treatment strategies improve for these patients. Some background Patients with HL need to be treated...

Read More

Evaluating combined modality treatment for young adults with Hodgkin lymphoma

Posted by on Dec 7, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study determined the safety and effectiveness of combined modality treatment for young adults with classical Hodgkin lymphoma (cHL). This study concluded that this treatment approach was well-tolerated and effective for these patients. Some background Chemotherapy regimens for pediatric patients with cHL are different from...

Read More

Evaluating pembrolizumab for patients with primary mediastinal large B-cell lymphoma that has come back or stopped responding to treatment

Posted by on Nov 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) for patients with primary mediastinal large B-cell lymphoma (PMBCL) that has come back or stopped responding to treatment. This study concluded that pembrolizumab was safe and effective for these patients. Some background PMBCL is one rare and aggressive type...

Read More

What factors can predict the success of stem cell transplantation for patients with lymphoma?

Posted by on Nov 3, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the risk factors associated with delayed engraftment in patients who had stem cell transplantation (SCT). The authors found that patients receiving blood transfusions, those with low platelet levels, and those given low numbers of stem cells during SCT were more likely to experience DE. Some...

Read More

Evaluating brentuximab vedotin for patients with relapsed or unresponsive Hodgkin lymphoma after SCT

Posted by on Oct 27, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the effectiveness of brentuximab vedotin (Adcetris) to chemotherapy in patients with classical Hodgkin’s lymphoma (cHL) that came back or stopped responding after a stem cell transplant (SCT). This study concluded that patients treated with brentuximab vedotin had better outcomes compared to patients in the...

Read More

Lymphoma transformation risk in patients with advanced follicular lymphoma

Posted by on Sep 20, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the frequency of lymphoma transformation in patients with advanced-stage follicular lymphoma (FL) after treatment with BR (bendamustine, rituximab). This study concluded these patients might be at risk for lymphoma transformation after initial treatment. Some background FL is the second most common type of...

Read More